Translucent AI

The company has secured significant funding, including a $7 million seed round in August 2025, backed by investors such as NEA, Virtue, FPV, and Redesign Health. This was quickly followed by a preemptive and oversubscribed Series A round of $27 million in March 2026, led by GV (Google Ventures), signaling strong market confidence. This capital is intended to accelerate product development and expand the company's team to serve more health systems across the United States.

Translucent's core offering is an agentic AI platform that functions as a dedicated financial analyst for every department and service line within a healthcare organization. It consolidates operational, clinical, and financial data from disparate sources like general ledgers, EHRs, and revenue cycle management systems into a unified, real-time view. A key feature is its natural language chat-based interface, which allows non-technical users, such as clinical and operational leaders, to ask complex financial questions and receive immediate, understandable answers and reports. The platform is designed to identify root causes of financial issues as they emerge, track performance against budgets, and analyze profitability by service line, department, and payer contracts. By automating up to 97% of routine financial analysis, the platform aims to free up finance teams to focus on strategic decision-making rather than manual data reconciliation.